Adjuncts in cancer chemotherapy

Details Adjuncts in cancer chemotherapy Adjuncts in cancer chemotherapy

1991-02-11

1992-05-19

Ivy, C. Warren

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 34, 514212, 514318, 514325, 530318, 536 64, 540478, 546194, 546203, A61K 3155, A61K 3170, C07D21170

Patent

active

051149192

ABSTRACT:
Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.

REFERENCES:
patent: 4031222 (1977-06-01), Remy
patent: 4031223 (1977-06-01), Remy
patent: 4990538 (1991-02-01), Harris
Ganapathi et al., Cancer Res. 43 3696 (1983).
Randall et al., J. Med. Chem. 22 1222 (1979).
Remy et al., J. Org. Chem. 41 1644 (1976).
Remy et al., J. Med Chem. 20 1013 (1977).
Rogan et al., Science 224 994 (1984).
Rothenberg et al., J. Nat. Cancer Inst. 81 907 (1989).
Tsuruo et al., Cancer Res. 41 1967 (1981).
Tsuruo et al., Cancer Res. 42 4730 (1982).
Tsuruo et al., Cancer Res. 43 2905 (1983).

Affiliated with

Also associated with

Rating

Adjuncts in cancer chemotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adjuncts in cancer chemotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuncts in cancer chemotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2417547